FDA Review on Novartis Galvus Extended
13th Nov 2006, 21:51 GMT
Swiss drugmaker Novartis AG said the US FDA will take until late 2/3/2006 months longer than anticipated -- to decide on the approval of diabetes drug Galvus, thereby extending the lead of a rival treatment by US competitor Merck.
FDA Review on Novartis Galvus Extended related news:
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- Novartis Diebetes Drug Gets FDA Setback — StratWire - Business of Healthcare NewsFeed
- Novartis announces three-month extension of US regulatory review for Galvus® to assess recently available clinical data — WebWire - Recent Headlines
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- European stocks mixed in early trade — Reuters: Shares
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- Novartis diabetes drug delayed — FT.com - Companies
- FDA Grants Priority Review for Soliris(TM) (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — PR Newswire: All Releases
- Review of Sanofi Drug Is Sought — WSJ.com: US Business
Latest news from Government/ Industry Regulation News from StratCenter.com:
- PLC Systems to Show RenalGuard at Medica 2006
- National Public Health Summit Targets Cervical Cancer Elimination
- MediPurpose Announces Exclusive Distribution Agreement for Sangofer Blood Separation Product
- Portrait PSR3 by Rhytec named in TIME Magazine's 2006 Skin Technology Story
- Pharsight Invited to Present on Model-Based Drug Development rd Annual Australian Health and Medical Research Congress
- Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress of the Societe Internationale d'Urologie
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ
- Sector Election Boosts Stem Cells
- AUDIO From Medialink and AARP: Voters' Call for Change Signals New Directions for Health Care
- Schering-Plough CEO Calls on New Congress to 'Do What Is Right' for the Patient, Calls for 'Scorecards' to Rate Managed Care Performance